China approves first immuno-oncology drug in the form of BMS’s Opdivo for lung cancer, opening up a new potentially huge market for the class, but much will depend on pricing and reimbursement policies.
In a milestone for the treatment of cancer in the country, China has approved its first immuno-oncology therapy in the form of Bristol-Myers Squibb Co.’s Opdivo (nivolumab), but commercial prospects in the potentially huge market remain cloudy until the drug is priced and it becomes clearer if it may be reimbursed under major insurance schemes.
The PD-1-targeting therapy has been approved by the new China National Drug Administration for the treatment of locally advanced or...
Big pharma is increasingly looking east to restock its pipelines, a process that is helping to forge a new generation of mid-sized R&D-based companies in China and is reflected in their stock price performance.
The list of small-cap companies with the fastest-rising share prices so far this year is dominated by Chinese companies, underscoring their growing contribution to the global biopharma ecosystem.
Four Chinese companies have won approvals in China, the first anywhere, for novel drugs for diffuse large B-cell lymphoma, certain types of non-small cell lung cancer and influenza A.
BlissBio is to single-handedly move BB-1701, its eribulin-containing, HER2-targeting antibody-drug conjugate, into a global pivotal Phase II/III program for HER2-expressing, Enhertu-resistant breast cancer.
Glenmark’s managing director talks about IGI’s billion dollar-plus deal with AbbVie, ISB-2001’s striking data, the BEAT platform, other "exciting" pipeline assets and the "blood, sweat and tears" to get to this stage.
Four Chinese companies have won approvals in China, the first anywhere, for novel drugs for diffuse large B-cell lymphoma, certain types of non-small cell lung cancer and influenza A.
Plus deals involving TandemAI/Perpetual Medicines, Biocytogen/BeOne, Chugai/Gero, CStone/Istituto Gentili, Alembic/Utility, Brii/Joincare, HanchorBio/Henlius, Rakuten/Cyntec and more.
